Figure 3

ILT2 expression by T cell populations of healthy donors and metastatic melanoma patients. (A) Evaluation by flow cytometry of frequency of peripheral blood cells expressing FoxP3 among CD4+ T cells (healthy donors n = 19, melanoma patients n = 21) and (B-D) ILT2 among (B) CD4+ T cells (healthy donors n = 11, melanoma patients n = 11), (C) CD8+ T cells (healthy donors n = 10, melanoma patients n = 11), and (D) CD4+FoxP3+ T cells (healthy donors n = 11, melanoma donors n = 11).